Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (IMLFF)

Inmed Pharmaceuticals Inc (IMLFF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1084 +38.38%
on 03/16/20
0.2402 -37.55%
on 03/09/20
-0.0810 (-35.06%)
since 03/06/20
3-Month
0.1084 +38.38%
on 03/16/20
0.3220 -53.42%
on 01/21/20
-0.0475 (-24.05%)
since 01/06/20
52-Week
0.1084 +38.38%
on 03/16/20
0.4160 -63.94%
on 04/08/19
-0.2480 (-62.31%)
since 04/05/19

Most Recent Stories

More News
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.1500 (+3.45%)
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER , April 1, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.1500 (+3.45%)
IN.TO : 0.20 (-4.76%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.1500 (+3.45%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

VANCOUVER , March 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.1500 (+3.45%)
IN.TO : 0.20 (-4.76%)
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.1500 (+3.45%)
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

VANCOUVER , March 20, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IN.TO : 0.20 (-4.76%)
IMLFF : 0.1500 (+3.45%)
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.1500 (+3.45%)
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER , March 10, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.1500 (+3.45%)
IN.TO : 0.20 (-4.76%)
Edison issues update on InMed Pharmaceuticals (IN)

LONDON, UK / ACCESSWIRE / February 20, 2020 / InMed Pharmaceuticals (TSX:IN) recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis...

IMLFF : 0.1500 (+3.45%)
IN.TO : 0.20 (-4.76%)
InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

Commenced Dosing of Patients in Phase 1 Clinical Trial with INM-755 -

IMLFF : 0.1500 (+3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IMLFF with:

Key Turning Points

2nd Resistance Point 0.1647
1st Resistance Point 0.1549
Last Price 0.1500
1st Support Level 0.1341
2nd Support Level 0.1231

See More

52-Week High 0.4160
Fibonacci 61.8% 0.2985
Fibonacci 50% 0.2622
Fibonacci 38.2% 0.2259
Last Price 0.1500
52-Week Low 0.1084

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar